Dem calls on DOJ to reject EpiPen settlement

Dem calls on DOJ to reject EpiPen settlement
© Greg Nash

Sen. Richard Blumenthal (D-Conn.) is calling on the Department of Justice (DOJ) to reject a settlement with the maker of EpiPens and instead press on with its investigation of the company, Mylan. 


Blumenthal's call comes after an announcement by Mylan earlier this month that it had reached a $465 million settlement with the DOJ over claims that the company overcharged the Medicaid program for years by misclassifying EpiPens as the wrong type of drug. 

The settlement, however, involved no admission of wrongdoing by Mylan, and Blumenthal cited estimates that the company could have overcharged by more than $700 million. 

“A settlement that lacks any acknowledgement of responsibility and requires payment smaller than profits made illegally at taxpayer expense is simply unacceptable,” Blumenthal wrote in a letter to the DOJ.  

“The American people have been rightly outraged by Mylan’s apparent profiteering and price gouging and possible fraud,” he said. “DOJ must fulfill its responsibility to fully and fairly investigate the facts, establish intent, and punish wrongdoing to deter present and future bad actors.”

Mylan has been the subject of outrage on both sides of the aisle recently for its more than 400 percent price increases in recent years for its life-saving allergy treatment. 

Senate Judiciary Committee Chairman Chuck GrassleyCharles (Chuck) Ernest GrassleyOvernight Health Care — Presented by National Taxpayers Union — Drug pricing fight centers on insulin | Florida governor working with Trump to import cheaper drugs | Dems blast proposed ObamaCare changes Drug pricing fight centers on insulin On The Money: Smaller tax refunds put GOP on defensive | Dems question IRS on new tax forms | Warren rolls out universal child care proposal | Illinois governor signs bill for minimum wage MORE (R-Iowa) has pressed the DOJ for details of the settlement.